Objective To investigate the effect of platinum-containing regimen combined with chemotherapy on the prognosis of patients aged over 70 years with advanced non-small cell lung cancer (NSCLC).

Methods  Through a retrospective cohort study, patients with NSCLC aged ≥70 years who were admitted to Anning First People's Hospital from June 2016 to June 2019 were selected as the study subjects, and the patients were divided into chemotherapy group and best supportive care (BSC) group according to the treatment methods, the survival rates of the two groups were compared, and the relevant factors affecting the survival and prognosis of elderly NSCLC patients were analyzed.

Results  A total of 305 patients were included. The medians survival of patients in chemotherapy group and BSC group were 11 months and 2 months, respectively. Kaplan-Meier survival analysis showed that the 6-month (76.5% vs. 17.9%, P<0.001), 1-year (51.9% vs. 12.1%, P<0.001) and 3-year (23.5% vs. 0%, P<0.001) survival rates in the chemotherapy group were significantly higher than those in the BSC group. The 3-year survival rates of patients aged <75 years and ≥75 years were 7.6% and 4.5%, respectively. There was no statistically significant difference in the total 3-year survival period between two groups (P=0.491). Cox multivariate analysis showed that complications and treatment methods were independent factors affecting the prognosis of patients aged over 70 years with advanced NSCLC (P<0.05).

Conclusion  The prognosis of elderly NSCLC patients receiving platinum-containing regimen combined with chemotherapy is significantly better than that of patients receiving BSC, and the treatment regimens and complications are independent risk factors affecting the poor prognosis of elderly NSCLC patients.

1.国家癌症中心, 国家肿瘤质控中心肺癌质控专家委员会. 中国原发性肺癌规范诊疗质量控制指标(2022版)[J]. 中华肿瘤杂志, 2022, 44(7): 594-599. [National Cancer Center, Expert Committee of Quality Control Center for Lung Cancer, National Quality Control Center for Cancer. Quality control index for standardized diagnosis and treatment of lung cancer in China (2022 edition)[J].Chinese Journal of Oncology, 2022, 44(7): 594-599.] DOI: 10.3760/cma.j.cn112152-20220418-00266.

2.Zhang L, Zhang FY, Li GF. Traditional Chinese medicine and lung cancer—from theory to practice[J]. Biomed Pharmacother, 2021, 137: 111381. DOI: 10.1016/j.biopha.2021.111381.

3.DeSantis CE, Miller KD, Dale W, et al. Cancer statistics for adults aged 85 years and older, 2019[J]. CA Cancer J Clin, 2019, 69(6): 452-467. DOI: 10.3322/caac.21577.

4.刘宁红. 70岁以上非小细胞肺癌单药培美曲塞一线治疗临床观察[J]. 中国老年学杂志, 2010, 30(13): 1880-1881. [Liu NH. Clinical observation on first-line treatment of non-small cell lung cancer aged 70 and above with single drug pemetrexed[J]. Chinese Journal of Gerontology, 2010, 30(13): 1880-1881.] DOI: 10.3969/j.issn.1005-9202.2010.13.047.

5.Li S, Lin Y, Wu Y, et al. The value of serum exosomal miR-184 in the diagnosis of NSCLC[J]. J Healthc Eng, 2022, 2022: 9713218. DOI: 10.1155/2022/9713218.

6.Zhang YW, Lu PP, Li YJ, et al. Prevalence, characteristics, and associated risk factors of the elderly with hip fractures: a cross-sectional analysis of NHANES 2005-2010[J]. Clin Interv Aging, 2021, 16: 177-185. DOI: 10.2147/CIA.S291071.

7.杨森, 谢颂平, 龙杏林, 等. 术前免疫检查点抑制剂联合化疗治疗可切除Ⅲ期非小细胞肺癌的疗效及患者近期预后的影响因素分析[J].实用心脑肺血管病杂志, 2022, 30(10): 26-32. [Yang S, Xie SP, Long XL, et al. Efficacy of preoperative immune checkpoint inhibitor combined with chemotherapy in the treatment of resectable stage Ⅲ non-small cell lung cancer and influencing factors of short-term prognosis of patients[J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 2022, 30(10): 26-32.] DOI: 10.12114/j.issn.1008-5971.2022.00.226.

8.Narayan V, Kahlmeyer A, Dahm P, et al. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane rapid review[J]. Cochrane Database Syst Rev, 2018, 7(7): CD012838. DOI: 10.1002/14651858.CD012838.pub2.

9.U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement[J]. Ann Intern Med, 2008, 149(3): 185-191. DOI: 10.7326/0003-4819-149-3-200808050-00008.

10.Kim JH. Chemotherapy for colorectal cancer in the elderly[J]. World J Gastroenterol, 2015, 21(17): 5158-5166. DOI: 10.3748/wjg.v21.i17.5158.

11.Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials[J]. J Clin Oncol, 2003, 21(7): 1383-1389. DOI: 10.1200/JCO.2003.08.010.

12.Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration[J]. J Clin Oncol, 2004, 22(22): 4626-4631. DOI: 10.1200/JCO.2004.02.175.

13.Balducci L. Geriatric oncology: challenges for the new century[J]. Eur J Cancer, 2000, 36(14): 1741-1754. DOI: 10.1016/s0959-8049(00)00169-6.

14.Ye H, Shao M, Shi X, et al. Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients[J]. Sci Rep, 2017, 7(1): 2670. DOI: 10.1038/s41598-017-02833-7.

15.李爱武, 周彩存, 徐建芳, 等. 长春瑞宾单药与长春瑞宾联合卡铂治疗≥75岁的老年晚期非小细胞肺癌患者的临床研究[J]. 同济大学学报(医学版), 2012, 33(4): 57-62. [Li AW, Zhou CC, Xu JF, et al. Vinorelbine versus vinorelbine-carboplatin in treatment of elderly patients with advanced non-small cell lung cancer[J]. Journal of Tongji University (Medical Science), 2012, 33(4): 57-62.] DOI: 10.3969/j.issn.1008-0392.2012.04.013.

16.Zhao Q, Hu G, Xiao W, et al. Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: a retrospective cohort study[J]. Medicine (Baltimore), 2017, 96(35): e7920. DOI: 10.1097/MD.0000000000007920.

17.Shi Y, Yang J, Yao N, et al. Factors affecting the survival of patients with oligometastatic non-small-cell lung cancer: a Meta-analysis[J]. Can Respir J, 2019, 2019: 2153170. DOI: 10.1155/2019/2153170.

18.Bradley JD, Hu C, Komaki RR, et al. Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer[J]. J Clin Oncol, 2020, 38(7): 706-714. DOI: 10.1200/JCO.19.01162.

19.段桦, 胡凯文, 崔慧娟, 等. 108例老年晚期非小细胞肺癌患者预后因素分析[J]. 癌症进展, 2020, 18(5): 470-474. [Duan H, Hu KW, Cui HJ, et al. Multivariate analysis of prognostic factors in the elderly patients with advanced non-small cell lung cancer: a study of 108 patients[J]. Oncology Progress, 2020, 18(5): 470-474.] DOI: 10.11877/j.issn.1672-1535.2020.18.05.11.

20.张贝贝, 田应选, 霍树芬, 等. 老年晚期非小细胞肺癌患者治疗方式与预后的相关性分析[J]. 实用心脑肺血管病杂志, 2021, 29(8): 53-59. [Zhang BB, Tian YX, Huo SF, et al. Correlation analysis of treatment and prognosis in elderly patients with advanced non-small cell lung cancer[J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 2021, 29(8): 53-59.] DOI: 10.12114/j.issn.1008-5971.2021.00.163.

21.Fan W, Xu L, Zheng H. Using multisource data to assess PM2.5 exposure and spatial analysis of lung cancer in Guangzhou, China[J]. Int J Environ Res Public Health, 2022, 19(5): 2629. DOI: 10.3390/ijerph19052629.

22.Remen T, Pintos J, Abrahamowicz M, et al. Risk of lung cancer in relation to various metrics of smoking history: a case-control study in Montreal[J]. BMC Cancer, 2018, 18(1): 1275. DOI: 10.1186/s12885-018-5144-5.

23.Zheng S, Wang R, Zhang Y, et al. Former smokers with non-small-cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis[J]. Cancer Med, 2016, 5(8): 2117-2125. DOI: 10.1002/cam4.764.

24.